{
    "Clinical Trial ID": "NCT00900627",
    "Intervention": [
        "INTERVENTION 1: ",
        "  AZD8931 160 mg bd",
        "  Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle",
        "INTERVENTION 2: ",
        "  AZD8931 120 mg bd",
        "  Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Male/ female with solid, malignant tumour which is unresponsive to standard therapies (Phase I). Female patients with advanced breast cancer with low HER2 expression (Phase II)",
        "  Suitable for paclitaxel chemotherapy",
        "  Life expectancy more than 12 weeks",
        "Exclusion Criteria:",
        "  Inadequate kidney, liver, heart, gastric, lung or eye function",
        "  Hypersensitive to paclitaxel",
        "  No symptomatic uncontrolled brain metastases",
        "  Previous taxane chemotherapy within 12 months (Phase II)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Phase I: The Number of Dose Limiting Toxicities in AZD8931 in Combination With Weekly Paclitaxel",
        "  DLT is an AE or laboratory abnormality related to AZD8931, starting during the DLT evaluation period and meeting any of the following criteria (further detail in protocol): Symptomatic ocular surface lesion; CTCAE grade 4 haematological AE; CTCAE grade 3 of febrile neutropenia / neutropenia / thrombocytopenia / hyperkalaemia / hyperglycaemia / hypotension / urological toxicity / ILD / pneumonitis; QTcF interval > 500 msec, two ECGs  30 minutes apart; Symptomatic congestive cardiac failure and a drop in LVEF; Decrease in LVEF of 20% to below the LLN; CS rash remaining CTCAE grade 3 for 5 days despite optimal treatment; CTCAE grade 3 nausea, vomiting or diarrhoea, despite optimal therapy; Other CTCAE grade 3 toxicity which, in the opinion of the investigator, is CS and related to AZD8931; Delay to the administration of paclitaxel on D1 of Cycle 2 by 7 days. Patients could have more than one DLT.",
        "  Time frame: Weekly visits for routine safety monitoring from Day 1 to Day 28 for each participant",
        "Results 1: ",
        "  Arm/Group Title: AZD8931 160 mg bd",
        "  Arm/Group Description: Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: Number of Dose Limiting Toxicities  Total: 2",
        "  Eye disorders: Keratitis: 1",
        "  Eye disorders: Photophobia: 1",
        "  Gastrointestinal disorders: Diarrhoea: 1",
        "  Gastrointestinal disorders: Oesophagitis: 0",
        "  Infections and infestations: Rash pustular: 0",
        "Results 2: ",
        "  Arm/Group Title: AZD8931 120 mg bd",
        "  Arm/Group Description: Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle",
        "  Overall Number of Participants Analyzed: 2",
        "  Measure Type: Number",
        "  Unit of Measure: Number of Dose Limiting Toxicities  Total: 1",
        "  Eye disorders: Keratitis: 0",
        "  Eye disorders: Photophobia: 0",
        "  Gastrointestinal disorders: Diarrhoea: 1",
        "  Gastrointestinal disorders: Oesophagitis: 0",
        "  Infections and infestations: Rash pustular: 0"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 4/6 (66.67%)",
        "  ANAEMIA 0/6 (0.00%)",
        "  FEBRILE NEUTROPENIA 0/6 (0.00%)",
        "  NEUTROPENIA 0/6 (0.00%)",
        "  PANCYTOPENIA 0/6 (0.00%)",
        "  CARDIAC FAILURE 0/6 (0.00%)",
        "  ATRIAL FIBRILLATION 0/6 (0.00%)",
        "  MYOCARDIAL INFARCTION 0/6 (0.00%)",
        "  SUPRAVENTRICULAR TACHYCARDIA 0/6 (0.00%)",
        "  KERATITIS 0/6 (0.00%)",
        "  DIARRHOEA 0/6 (0.00%)",
        "  NAUSEA 0/6 (0.00%)",
        "  OESOPHAGITIS 0/6 (0.00%)",
        "Adverse Events 2:",
        "  Total: 2/6 (33.33%)",
        "  ANAEMIA 0/6 (0.00%)",
        "  FEBRILE NEUTROPENIA 0/6 (0.00%)",
        "  NEUTROPENIA 0/6 (0.00%)",
        "  PANCYTOPENIA 0/6 (0.00%)",
        "  CARDIAC FAILURE 0/6 (0.00%)",
        "  ATRIAL FIBRILLATION 0/6 (0.00%)",
        "  MYOCARDIAL INFARCTION 0/6 (0.00%)",
        "  SUPRAVENTRICULAR TACHYCARDIA 0/6 (0.00%)",
        "  KERATITIS 0/6 (0.00%)",
        "  DIARRHOEA 0/6 (0.00%)",
        "  NAUSEA 0/6 (0.00%)",
        "  OESOPHAGITIS 1/6 (16.67%)"
    ]
}